Literature DB >> 14513205

Development of analytical technology in pharmacogenetic research.

Ann K Daly1.   

Abstract

Methods used to determine phenotype and genotype for pharmacogenetic polymorphisms are discussed. Phenotyping is mainly applicable to polymorphisms affecting drug disposition rather than drug response and can involve either direct measurement of enzyme activity or administration of a probe drug followed by measurement of drug and/or metabolite levels. Genotyping is now more widely used than phenotyping and can be used to determine genotype for polymorphisms affecting either drug disposition (for example those in the cytochromes P450 or N-acetyltransferases) or drug response (for example those in drug receptors). Most genotyping for known polymorphisms involves use of the polymerase chain reaction and the wide variety of methods based on this technique that are now used for routine genotyping are discussed in detail. In addition, a range of methods that can be used to detect novel polymorphisms, thereby further increasing understanding of interindividual variability in drug disposition and response, is described.

Mesh:

Substances:

Year:  2003        PMID: 14513205     DOI: 10.1007/s00210-003-0794-4

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  64 in total

1.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

2.  Human acetyltransferase polymorphisms.

Authors:  D M Grant; N C Hughes; S A Janezic; G H Goodfellow; H J Chen; A Gaedigk; V L Yu; R Grewal
Journal:  Mutat Res       Date:  1997-05-12       Impact factor: 2.433

3.  CYP2D6 multiallelism.

Authors:  A K Daly; V M Steen; K S Fairbrother; J R Idle
Journal:  Methods Enzymol       Date:  1996       Impact factor: 1.600

4.  Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5' modification, purification, spectral characterization, reconstitution conditions, and catalytic activities.

Authors:  E M Gillam; Z Guo; Y F Ueng; H Yamazaki; I Cock; P E Reilly; W D Hooper; F P Guengerich
Journal:  Arch Biochem Biophys       Date:  1995-03-10       Impact factor: 4.013

5.  Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans.

Authors:  M Nakajima; T Yokoi; M Mizutani; M Kinoshita; M Funayama; T Kamataki
Journal:  J Biochem       Date:  1999-04       Impact factor: 3.387

6.  A urinary metabolite ratio that reflects systemic caffeine clearance.

Authors:  M E Campbell; S P Spielberg; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1987-08       Impact factor: 6.875

7.  Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes.

Authors:  R E Kouri; C E McKinney; D J Slomiany; D R Snodgrass; N P Wray; T L McLemore
Journal:  Cancer Res       Date:  1982-12       Impact factor: 12.701

8.  Genetic polymorphism for human platelet thermostable phenol sulfotransferase (TS PST) activity.

Authors:  R A Price; R S Spielman; A L Lucena; J A Van Loon; B L Maidak; R M Weinshilboum
Journal:  Genetics       Date:  1989-08       Impact factor: 4.562

9.  Polymorphic N-acetylation of a caffeine metabolite.

Authors:  D M Grant; B K Tang; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1983-03       Impact factor: 6.875

10.  Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam.

Authors:  M Patel; B K Tang; D M Grant; W Kalow
Journal:  Pharmacogenetics       Date:  1995-10
View more
  1 in total

Review 1.  The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.

Authors:  Jose de Leon; Margaret T Susce; Elaina Murray-Carmichael
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.